Research Notice: This article covers research on Retatrutide research peptide and Tirzepatide research peptide — available from Palmetto Peptides for laboratory use only.

Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.

Palmetto Peptides Complete Guide to the Research Peptide Retatrutide

Legal Disclaimer: All information in this article is provided for educational and informational purposes only. Retatrutide (LY3437943) is an investigational research peptide. It has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for therapeutic, diagnostic, or preventive use in humans or animals. Products sold by Palmetto Peptides are intended exclusively for in vitro laboratory research by qualified scientific professionals. Nothing in this article constitutes medical advice, and no information here should be interpreted as a recommendation to use, administer, or obtain any compound for personal use. Always consult a licensed healthcare provider for medical guidance.

Last Updated: March 30, 2026 | Reading Time: Approximately 24 minutes | Author: Palmetto Peptides Research Team

Quick Answer

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that simultaneously activates three metabolic receptors -- GIP, GLP-1, and glucagon receptors -- making it the first-in-class triple incretin receptor agonist in advanced preclinical and clinical research.

14. Peer-Reviewed Citations

The following peer-reviewed and primary sources were referenced in the preparation of this article. Researchers are encouraged to consult original publications for complete methodological detail.

1. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. https://doi.org/10.1016/j.cmet.2022.08.007

2. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity -- A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. https://doi.org/10.1056/NEJMoa2301972

3. Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. https://doi.org/10.1016/S0140-6736(23)01053-X

4. Sanyal AJ, Bedossa P, Fraessdorf M, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://doi.org/10.1038/s41591-024-03018-2

5. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;399(10326):1869-1881. https://doi.org/10.1016/S0140-6736(22)00682-3

6. Rajagopal S, Bhardwaj G, Jain A, Bhardwaj V, Siddiqui SA, Ahlawat A. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor University Medical Center Proceedings. 2025;38(3):291-303. https://doi.org/10.1080/08998280.2025.2456441

7. Liu Q, Yang D, Zhuang Y, Croll TI, Cai X, Dai A, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:72. https://doi.org/10.1038/s41421-024-00700-0

8. Lautenbach A, Gonnermann A, Blüher M. Triple Agonism Based Therapies for Obesity. Current Cardiovascular Risk Reports. 2025. https://doi.org/10.1007/s12170-025-00770-z

9. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Investor Relations Press Release. 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

Disclaimer (Repeated for Compliance): Retatrutide is an investigational research peptide. It is not approved by the FDA or any other regulatory authority for therapeutic use in humans or animals. All products offered by Palmetto Peptides are for in vitro laboratory research only. Nothing in this article constitutes medical advice, a treatment recommendation, or an endorsement of self-administration. Researchers are responsible for ensuring their use of research chemicals complies with all applicable laws and institutional regulations.

Article prepared by the Palmetto Peptides Research Team.**

Related research: what is retatrutide, retatrutide vs tirzepatide comparison, and GLP-1 agonist research comparison 2026.

Related Research Articles

• Retatrutide: What Researchers Need to Know About the Triple Agonist
• Tirzepatide vs. Retatrutide: Research Comparison
• Cagrilintide 2026 Research Update: Preclinical Metabolic and Weight Findings
• Retatrutide Reconstitution Calculator: Research Dose and Volume Reference